MXPA05000773A - Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad. - Google Patents
Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad.Info
- Publication number
- MXPA05000773A MXPA05000773A MXPA05000773A MXPA05000773A MXPA05000773A MX PA05000773 A MXPA05000773 A MX PA05000773A MX PA05000773 A MXPA05000773 A MX PA05000773A MX PA05000773 A MXPA05000773 A MX PA05000773A MX PA05000773 A MXPA05000773 A MX PA05000773A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- juxtacleral
- anecortave acetate
- treatment
- patients
- Prior art date
Links
- 206010064930 age-related macular degeneration Diseases 0.000 title claims abstract description 35
- 230000004304 visual acuity Effects 0.000 title claims abstract description 28
- 229960001232 anecortave Drugs 0.000 title claims description 67
- YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 title claims description 64
- 208000002780 macular degeneration Diseases 0.000 title abstract description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 230000003902 lesion Effects 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 239000007943 implant Substances 0.000 claims description 12
- 230000005764 inhibitory process Effects 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 210000004204 blood vessel Anatomy 0.000 claims description 6
- 230000017066 negative regulation of growth Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 12
- -1 anecortave acetate compound Chemical class 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 description 77
- 239000000902 placebo Substances 0.000 description 34
- 229940068196 placebo Drugs 0.000 description 34
- 230000004438 eyesight Effects 0.000 description 33
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 27
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 27
- 201000004569 Blindness Diseases 0.000 description 15
- 238000004321 preservation Methods 0.000 description 15
- 230000004393 visual impairment Effects 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 208000014674 injury Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 206010029113 Neovascularisation Diseases 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 230000000964 angiostatic effect Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- 208000002177 Cataract Diseases 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 208000018769 loss of vision Diseases 0.000 description 5
- 231100000864 loss of vision Toxicity 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 230000000873 masking effect Effects 0.000 description 4
- 231100001035 ocular change Toxicity 0.000 description 4
- 230000000649 photocoagulation Effects 0.000 description 4
- 238000002428 photodynamic therapy Methods 0.000 description 4
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- 206010052140 Eye pruritus Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 231100000279 safety data Toxicity 0.000 description 3
- 206010010719 Conjunctival haemorrhage Diseases 0.000 description 2
- 206010055665 Corneal neovascularisation Diseases 0.000 description 2
- 206010015958 Eye pain Diseases 0.000 description 2
- 206010015995 Eyelid ptosis Diseases 0.000 description 2
- 206010024214 Lenticular opacities Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 201000000159 corneal neovascularization Diseases 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000010595 endothelial cell migration Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 2
- 229960004657 indocyanine green Drugs 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 201000003004 ptosis Diseases 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 238000011268 retreatment Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 201000009487 Amblyopia Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- 208000007135 Retinal Neovascularization Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 208000036488 Scleral thinning Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- UESYMIFUVPHBHL-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O.CC(O)=O.CC(O)=O UESYMIFUVPHBHL-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 201000007917 background diabetic retinopathy Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000001046 green dye Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 230000010494 opalescence Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- 208000022749 pupil disease Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40122002P | 2002-08-05 | 2002-08-05 | |
| PCT/US2003/020154 WO2004012742A1 (en) | 2002-08-05 | 2003-06-26 | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05000773A true MXPA05000773A (es) | 2005-04-19 |
Family
ID=31495940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05000773A MXPA05000773A (es) | 2002-08-05 | 2003-06-26 | Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20040127472A1 (https=) |
| EP (1) | EP1539182A4 (https=) |
| JP (1) | JP2005535691A (https=) |
| KR (1) | KR20050026510A (https=) |
| CN (1) | CN1674913A (https=) |
| AR (1) | AR040599A1 (https=) |
| AU (1) | AU2003281817A1 (https=) |
| BR (1) | BR0313546A (https=) |
| CA (1) | CA2494211A1 (https=) |
| DE (1) | DE03742226T1 (https=) |
| ES (1) | ES2244361T1 (https=) |
| MX (1) | MXPA05000773A (https=) |
| PL (1) | PL375024A1 (https=) |
| RU (1) | RU2322239C2 (https=) |
| TW (1) | TW200410699A (https=) |
| WO (1) | WO2004012742A1 (https=) |
| ZA (1) | ZA200500731B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040127472A1 (en) * | 2002-08-05 | 2004-07-01 | Jerdan Janice A. | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
| MXPA05008396A (es) * | 2003-02-20 | 2006-03-30 | Alcon Inc | Formulaciones de glucocorticoides para tratar angiogenesis ocular patologica. |
| AU2004249256A1 (en) * | 2003-06-20 | 2004-12-29 | Alcon, Inc. | Treatment of AMD with combination of ingredients |
| CA2539023A1 (en) * | 2003-09-23 | 2005-04-14 | Alcon Inc. | Triamcinolone acetonide and anecortave acetate formulations for injection |
| US7257366B2 (en) * | 2003-11-26 | 2007-08-14 | Osmosis Llc | System and method for teaching a new language |
| WO2005110374A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| US7261529B2 (en) * | 2005-09-07 | 2007-08-28 | Southwest Research Institute | Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
| US7758778B2 (en) * | 2005-09-07 | 2010-07-20 | Southwest Research Institute | Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
| US9693967B2 (en) * | 2005-09-07 | 2017-07-04 | Southwest Research Institute | Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates |
| US20070134244A1 (en) * | 2005-10-14 | 2007-06-14 | Alcon, Inc. | Combination treatment for pathologic ocular angiogenesis |
| MX2009006146A (es) * | 2006-12-18 | 2009-06-19 | Alcon Res Ltd | Dispositivos y metodos para la administracion de farmacos oftalmicos. |
| CN101759741B (zh) * | 2008-11-06 | 2013-01-09 | 天津金耀集团有限公司 | 一种化合物及其在制备治疗血管新生的药物中的应用 |
| CN101923856B (zh) | 2009-06-12 | 2012-06-06 | 华为技术有限公司 | 语音识别训练处理、控制方法及装置 |
| US20150037422A1 (en) * | 2012-02-22 | 2015-02-05 | Trustees Of Tufts College | Compositions and methods for ocular delivery of a therapeutic agent |
| RU2489146C1 (ru) * | 2012-07-11 | 2013-08-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) | Способ лечения "сухой" формы возрастной макулярной дегенерации |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4876250A (en) * | 1988-10-31 | 1989-10-24 | Alcon Laboratories, Inc. | Methods for controlling ocular hypertension with angiostatic steroids |
| RU2051651C1 (ru) * | 1988-07-07 | 1996-01-10 | Институт химии поверхности АН Украины | Основа для глазных капель |
| US5371078A (en) * | 1988-10-31 | 1994-12-06 | Alcon Laboratories, Inc. | Angiostatic steroids and methods and compositions for controlling ocular hypertension |
| US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
| US5679666A (en) * | 1991-11-22 | 1997-10-21 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids |
| ATE283013T1 (de) * | 1999-10-21 | 2004-12-15 | Alcon Inc | Medikamentenzuführvorrichtung |
| US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| US20040127472A1 (en) * | 2002-08-05 | 2004-07-01 | Jerdan Janice A. | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
| US20070134244A1 (en) * | 2005-10-14 | 2007-06-14 | Alcon, Inc. | Combination treatment for pathologic ocular angiogenesis |
-
2003
- 2003-06-26 US US10/606,501 patent/US20040127472A1/en not_active Abandoned
- 2003-06-26 PL PL03375024A patent/PL375024A1/xx unknown
- 2003-06-26 JP JP2004526013A patent/JP2005535691A/ja active Pending
- 2003-06-26 MX MXPA05000773A patent/MXPA05000773A/es not_active Application Discontinuation
- 2003-06-26 US US10/521,707 patent/US20060166956A1/en not_active Abandoned
- 2003-06-26 DE DE03742226T patent/DE03742226T1/de active Pending
- 2003-06-26 KR KR1020057001248A patent/KR20050026510A/ko not_active Ceased
- 2003-06-26 ES ES03742226T patent/ES2244361T1/es active Pending
- 2003-06-26 WO PCT/US2003/020154 patent/WO2004012742A1/en not_active Ceased
- 2003-06-26 AU AU2003281817A patent/AU2003281817A1/en not_active Abandoned
- 2003-06-26 BR BR0313546-2A patent/BR0313546A/pt not_active IP Right Cessation
- 2003-06-26 RU RU2005106234/14A patent/RU2322239C2/ru not_active IP Right Cessation
- 2003-06-26 EP EP03742226A patent/EP1539182A4/en not_active Withdrawn
- 2003-06-26 CN CNA038188260A patent/CN1674913A/zh active Pending
- 2003-06-26 CA CA002494211A patent/CA2494211A1/en not_active Abandoned
- 2003-07-07 TW TW092118474A patent/TW200410699A/zh unknown
- 2003-07-17 AR AR20030102575A patent/AR040599A1/es unknown
-
2005
- 2005-01-25 ZA ZA200500731A patent/ZA200500731B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR040599A1 (es) | 2005-04-13 |
| BR0313546A (pt) | 2005-07-12 |
| ZA200500731B (en) | 2006-08-30 |
| RU2005106234A (ru) | 2005-08-10 |
| KR20050026510A (ko) | 2005-03-15 |
| US20060166956A1 (en) | 2006-07-27 |
| AU2003281817A1 (en) | 2004-02-23 |
| CN1674913A (zh) | 2005-09-28 |
| TW200410699A (en) | 2004-07-01 |
| WO2004012742A1 (en) | 2004-02-12 |
| US20040127472A1 (en) | 2004-07-01 |
| PL375024A1 (en) | 2005-11-14 |
| DE03742226T1 (de) | 2006-03-09 |
| ES2244361T1 (es) | 2005-12-16 |
| JP2005535691A (ja) | 2005-11-24 |
| CA2494211A1 (en) | 2004-02-12 |
| EP1539182A1 (en) | 2005-06-15 |
| EP1539182A4 (en) | 2010-01-20 |
| RU2322239C2 (ru) | 2008-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Regillo et al. | Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 | |
| Tan et al. | Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye | |
| Jaffe et al. | Fluocinolone acetonide sustained drug delivery device to treat severe uveitis | |
| TWI260327B (en) | Pharmaceutical compositions for treating ocular neovascular diseases | |
| RU2572707C2 (ru) | Глазные капли с дифлупреднатом для лечения отека желтого пятна | |
| García-Arumí et al. | Vitreoretinal surgery for cystoid macular edema associated with retinitis pigmentosa | |
| MXPA05000773A (es) | Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad. | |
| WO2010125416A1 (en) | Drug delivery to the anterior and posterior segments of the eye | |
| Tang et al. | Efficacy of intravitreal ranibizumab combined with Ahmed glaucoma valve implantation for the treatment of neovascular glaucoma | |
| Ng et al. | Ocular complications of pediatric bone marrow transplantation | |
| US20070027102A1 (en) | Methods and compositions for treating macular degeneration | |
| US20130156841A1 (en) | Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids | |
| Hanif et al. | Safety and efficacy of suprachoroidal injection of triamcinolone in treating macular edema secondary to noninfectious uveitis | |
| EP1365771B1 (en) | Method of treating certain eye diseases | |
| Paccola et al. | Anti‐inflammatory efficacy of a single posterior subtenon injection of triamcinolone acetonide versus prednisolone acetate 1% eyedrops after pars plana vitrectomy | |
| Kumar et al. | Scleral buckle intrusion | |
| Kiernan et al. | Topical drug delivery for posterior segment disease | |
| Gull et al. | Intravitrealversus posterior subtenon triamcinolone acetonide in conjunction with intravitreal bevacizumab for refractory diabetic macular edema | |
| Simsek et al. | The efficacy of single-dose intravitreal dexamethasone implant for diabetic macular edema refractory to anti-VEGF therapy: real-life results | |
| Kępka et al. | Clinical features, diagnosis and management of serpiginuos choroiditis | |
| RU2770745C1 (ru) | Комбинированный способ лечения хориоидальной неоваскуляции всех типов | |
| Narayanaswamy et al. | Randomized, controlled trial of a sustained delivery formulation of 5-fluorouracil for the treatment of failing blebs | |
| de Koo | Central Serous? What Now? Management Options for Central Serous Retinopathy | |
| US20040259844A1 (en) | Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage | |
| Nivetha | Comparison of preoperative topical dexamethasone phosphate versus ketorolac tromethamine in maintaining intraoperative mydriasis during small incision cataract surgery–a one year randomized control trial at kles dr. prabhakar kore hospital and medical research centre, belagavi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |